Pub Date : 2025-01-10DOI: 10.1016/j.jfo.2024.104403
N. Yesilirmak , S. Yuzbasioglu , O. Saritas , A. Aktas , J.-L. Bourges
<div><h3>Objective</h3><div>To compare the corneal topographic parameters and ocular surface parameters of ocular rosacea (OR) patients across skin subtypes of the disease and healthy controls.</div></div><div><h3>Methods</h3><div>This prospective study included 180 eyes of 90 OR patients and 60 eyes of 30 healthy controls. Among the OR patients, 30 had phymatous (60 eyes), 30 had erythematotelangiectatic (60 eyes) and 30 had papulopustular skin types (60 eyes). We measured the mean keratometry (Kmean), maximum keratometry (Kmax), thinnest corneal thickness (TCT), central corneal thickness (CCT) and corneal volume (CV) with a topography device (Sirius, Italy). Additionally, we measured tear-film breakup time (TBUT), Meiboscore and Schirmer's test from all participants. We compared parameters across OR skin groups as well as with controls.</div></div><div><h3>Results</h3><div>Kmean and Kmax were significantly steeper in the OR group compared to controls (<em>p</em> <!--><<!--> <!-->0.05). We found significant correlations between “Kmean-Kmax”, “CV-TCT”, “CV-CCT”, and “TCT-CCT” in both groups, while significant correlations between “age-Kmean”, “age-Kmax”, and “Meiboscore-Kmax” were present only in OR patients. When patients were divided into subgroups according to their skin subtypes, the papulopustular and phymatous subgroups had steeper Kmean and Kmax compared to the erythematotelangiectatic and control groups (<em>P</em> <!--><<!--> <!-->0.05). The papulopustular subgroup had lower CCT, lower TBUT and higher Meiboscore compared to the phymatous, erythematotelangiectatic and control groups but lower TCT compared to controls (<em>P</em> <!--><<!--> <!-->0.05). In addition, there were significant correlations between “Kmax-CV”, “Kmax-TCT”, and “Kmax-meiboscore” only in the papulopustular subgroup (<em>P</em> <!--><<!--> <!-->0.05).</div></div><div><h3>Conclusion</h3><div>It appears that the corneas of OR patients are steeper than those of healthy controls; corneal thinning and abnormalities of ocular surface parameters are more pronounced in papulopustular skin types.</div></div><div><h3>Objectif</h3><div>Comparer les paramètres topographiques cornéens et les paramètres de la surface oculaire des patients atteints de rosacée oculaire (RO) selon les sous-types cutanés de la maladie et des témoins sains.</div></div><div><h3>Méthodes</h3><div>Cette étude prospective a inclus 180 yeux de 90 patients RO et 60 yeux de 30 témoins sains. Parmi les patients RO, 30 avaient une peau phymateuse (60 yeux), 30 une peau érythémato-télangiectasique (60 yeux) et 30 une peau papulo-pustuleuse (60 yeux). Nous avons mesuré la kératométrie moyenne (Kmean), la kératométrie maximale (Kmax), l’épaisseur cornéenne la plus fine (TCT), l’épaisseur cornéenne centrale (CCT) et le volume cornéen (CV) avec un appareil topographique (Sirius, Italie). De plus, nous avons mesuré le temps de rupture des larmes (TBUT), le meiboscore et faire le test de Schirmer de tous l
{"title":"Investigation of corneal topographic and ocular surface parameters in ocular rosacea based on skin subtypes","authors":"N. Yesilirmak , S. Yuzbasioglu , O. Saritas , A. Aktas , J.-L. Bourges","doi":"10.1016/j.jfo.2024.104403","DOIUrl":"10.1016/j.jfo.2024.104403","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the corneal topographic parameters and ocular surface parameters of ocular rosacea (OR) patients across skin subtypes of the disease and healthy controls.</div></div><div><h3>Methods</h3><div>This prospective study included 180 eyes of 90 OR patients and 60 eyes of 30 healthy controls. Among the OR patients, 30 had phymatous (60 eyes), 30 had erythematotelangiectatic (60 eyes) and 30 had papulopustular skin types (60 eyes). We measured the mean keratometry (Kmean), maximum keratometry (Kmax), thinnest corneal thickness (TCT), central corneal thickness (CCT) and corneal volume (CV) with a topography device (Sirius, Italy). Additionally, we measured tear-film breakup time (TBUT), Meiboscore and Schirmer's test from all participants. We compared parameters across OR skin groups as well as with controls.</div></div><div><h3>Results</h3><div>Kmean and Kmax were significantly steeper in the OR group compared to controls (<em>p</em> <!--><<!--> <!-->0.05). We found significant correlations between “Kmean-Kmax”, “CV-TCT”, “CV-CCT”, and “TCT-CCT” in both groups, while significant correlations between “age-Kmean”, “age-Kmax”, and “Meiboscore-Kmax” were present only in OR patients. When patients were divided into subgroups according to their skin subtypes, the papulopustular and phymatous subgroups had steeper Kmean and Kmax compared to the erythematotelangiectatic and control groups (<em>P</em> <!--><<!--> <!-->0.05). The papulopustular subgroup had lower CCT, lower TBUT and higher Meiboscore compared to the phymatous, erythematotelangiectatic and control groups but lower TCT compared to controls (<em>P</em> <!--><<!--> <!-->0.05). In addition, there were significant correlations between “Kmax-CV”, “Kmax-TCT”, and “Kmax-meiboscore” only in the papulopustular subgroup (<em>P</em> <!--><<!--> <!-->0.05).</div></div><div><h3>Conclusion</h3><div>It appears that the corneas of OR patients are steeper than those of healthy controls; corneal thinning and abnormalities of ocular surface parameters are more pronounced in papulopustular skin types.</div></div><div><h3>Objectif</h3><div>Comparer les paramètres topographiques cornéens et les paramètres de la surface oculaire des patients atteints de rosacée oculaire (RO) selon les sous-types cutanés de la maladie et des témoins sains.</div></div><div><h3>Méthodes</h3><div>Cette étude prospective a inclus 180 yeux de 90 patients RO et 60 yeux de 30 témoins sains. Parmi les patients RO, 30 avaient une peau phymateuse (60 yeux), 30 une peau érythémato-télangiectasique (60 yeux) et 30 une peau papulo-pustuleuse (60 yeux). Nous avons mesuré la kératométrie moyenne (Kmean), la kératométrie maximale (Kmax), l’épaisseur cornéenne la plus fine (TCT), l’épaisseur cornéenne centrale (CCT) et le volume cornéen (CV) avec un appareil topographique (Sirius, Italie). De plus, nous avons mesuré le temps de rupture des larmes (TBUT), le meiboscore et faire le test de Schirmer de tous l","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 3","pages":"Article 104403"},"PeriodicalIF":1.2,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-10DOI: 10.1016/j.jfo.2024.104372
D. Fraenkel , H. Kaymak , M. Hartmann , W. Aljundi , C. Munteanu , B. Seitz , A.D. Abdin
<div><h3>Purpose</h3><div>To investigate the morphologic and functional outcomes of nanosecond subthreshold (ST) laser treatment for patients with chronic central serous chorioretinopathy (CSC).</div></div><div><h3>Methods</h3><div>In this prospective study, 44 patients were treated with the ST nanosecond laser with a follow-up period of 12 months. All target variables were measured at 1, 3, 6 and 12 months after the first laser treatment.</div></div><div><h3>Results</h3><div>This study showed a significant improvement in macular sensitivity (MS), a significant reduction in central macular thickness (CMT) as well as a significant reduction in subretinal fluid height (SRF) after 3 months of treatment. The subfoveal choroidal thickness (SFCT) was significantly reduced after 12 months of treatment. However, the best-corrected visual acuity (BCVA) (logMAR) did not change significantly at any time during the study. A high proportion of patients (85%) showed complete resolution of SRF after 12 months, indicating a positive response to treatment in the majority of our patients.</div></div><div><h3>Conclusion</h3><div>This study showed statistically significant functional improvement in MS as well as significant anatomical reduction in CMT, SFCT and SRF height in CSC patients treated with ST nanosecond laser therapy. Patients with higher SRF at baseline required repeated laser treatments to achieve complete resolution of the SRF.</div></div><div><h3>Objectif</h3><div>Étudier les résultats morphologiques et fonctionnels du traitement au <em>subthreshold</em> (ST) <em>nanolaser</em> pour les patients atteints de choriorétinopathie centrale séreuse chronique (CCS).</div></div><div><h3>Méthodes</h3><div>Dans cette étude prospective, 44 patients ont été traités au ST <em>nanolaser</em> avec une période de suivi de 12 mois. Toutes les variables ont été mesurées à 1, 3, 6 et 12 mois après le premier traitement au laser.</div></div><div><h3>Résultats</h3><div>Cette étude a démontré une amélioration significative de la sensibilité maculaire (SM) et une réduction significative de l’épaisseur maculaire centrale (EMC), ainsi que de la hauteur du liquide sous-rétinien (LSR) après 3 mois de traitement. L’épaisseur choroïdienne sous-fovéale (ECSF) n’a été significativement réduite qu’après 12 mois de traitement. Cependant, la meilleure acuité visuelle corrigée (MAVC) (logMAR) n’a pas changé de manière significative durant l’étude. La majorité des patients (85 %) a montré une résolution complète du LSR après 12 mois, ce qui indique une réponse positive au traitement.</div></div><div><h3>Conclusion</h3><div>Cette étude a démontré une amélioration statistiquement significative de la SM ainsi qu’une réduction significative de l’EMT, de l’ECSF et de la hauteur du LSR chez les patients atteints de CCS traités au ST <em>nanolaser</em>. Les patients présentant un LSR plus élevé au départ ont dû subir plusieurs traitements pour obtenir une résolution complète du LSR.</div></div
{"title":"Subthreshold nanosecond laser therapy for chronic central serous chorioretinopathy: A prospective study","authors":"D. Fraenkel , H. Kaymak , M. Hartmann , W. Aljundi , C. Munteanu , B. Seitz , A.D. Abdin","doi":"10.1016/j.jfo.2024.104372","DOIUrl":"10.1016/j.jfo.2024.104372","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the morphologic and functional outcomes of nanosecond subthreshold (ST) laser treatment for patients with chronic central serous chorioretinopathy (CSC).</div></div><div><h3>Methods</h3><div>In this prospective study, 44 patients were treated with the ST nanosecond laser with a follow-up period of 12 months. All target variables were measured at 1, 3, 6 and 12 months after the first laser treatment.</div></div><div><h3>Results</h3><div>This study showed a significant improvement in macular sensitivity (MS), a significant reduction in central macular thickness (CMT) as well as a significant reduction in subretinal fluid height (SRF) after 3 months of treatment. The subfoveal choroidal thickness (SFCT) was significantly reduced after 12 months of treatment. However, the best-corrected visual acuity (BCVA) (logMAR) did not change significantly at any time during the study. A high proportion of patients (85%) showed complete resolution of SRF after 12 months, indicating a positive response to treatment in the majority of our patients.</div></div><div><h3>Conclusion</h3><div>This study showed statistically significant functional improvement in MS as well as significant anatomical reduction in CMT, SFCT and SRF height in CSC patients treated with ST nanosecond laser therapy. Patients with higher SRF at baseline required repeated laser treatments to achieve complete resolution of the SRF.</div></div><div><h3>Objectif</h3><div>Étudier les résultats morphologiques et fonctionnels du traitement au <em>subthreshold</em> (ST) <em>nanolaser</em> pour les patients atteints de choriorétinopathie centrale séreuse chronique (CCS).</div></div><div><h3>Méthodes</h3><div>Dans cette étude prospective, 44 patients ont été traités au ST <em>nanolaser</em> avec une période de suivi de 12 mois. Toutes les variables ont été mesurées à 1, 3, 6 et 12 mois après le premier traitement au laser.</div></div><div><h3>Résultats</h3><div>Cette étude a démontré une amélioration significative de la sensibilité maculaire (SM) et une réduction significative de l’épaisseur maculaire centrale (EMC), ainsi que de la hauteur du liquide sous-rétinien (LSR) après 3 mois de traitement. L’épaisseur choroïdienne sous-fovéale (ECSF) n’a été significativement réduite qu’après 12 mois de traitement. Cependant, la meilleure acuité visuelle corrigée (MAVC) (logMAR) n’a pas changé de manière significative durant l’étude. La majorité des patients (85 %) a montré une résolution complète du LSR après 12 mois, ce qui indique une réponse positive au traitement.</div></div><div><h3>Conclusion</h3><div>Cette étude a démontré une amélioration statistiquement significative de la SM ainsi qu’une réduction significative de l’EMT, de l’ECSF et de la hauteur du LSR chez les patients atteints de CCS traités au ST <em>nanolaser</em>. Les patients présentant un LSR plus élevé au départ ont dû subir plusieurs traitements pour obtenir une résolution complète du LSR.</div></div","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 3","pages":"Article 104372"},"PeriodicalIF":1.2,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-10DOI: 10.1016/j.jfo.2024.104406
A. Aulanier, N. Todd, N. Stolowy, M. Gonzalvez, T. David
<div><h3>Purpose</h3><div>To analyze the outcomes and frequency of complications after Descemet's membrane endothelial keratoplasty (DMEK) and evaluate the parameters associated with the occurrence of these complications.</div></div><div><h3>Methods</h3><div>A multicenter retrospective study of 143 DMEK procedures performed consecutively by five surgeons between June 2018 and March 2021 was performed. Surgeon-specific surgical and graft characteristics were also assessed. Data on best-corrected visual acuity (BCVA), central pachymetry, and endothelial cell density (ECD) were collected at one, three, six, and 12<!--> <!-->months. Postoperative complications and secondary procedures (rebubbling and regrafting) were also recorded.</div></div><div><h3>Results</h3><div>The mean BCVA at one year was 0.17 logMAR (±0.19). There was a mean hyperopic shift at one year of +0.26 diopters. The mean pachymetry at one year was 526<!--> <!-->μm (±53). The mean ECD at one year was 1164<!--> <!-->cells/mm<sup>2</sup> (±479). Graft detachment occurred in 51% of the procedures and was significantly associated with the performance of an intraoperative iridotomy (OR<!--> <!-->=<!--> <!-->2.8) [95% CI: 1.2–6.6]. Rebubbling occurred in 34% of the procedures, and a new graft was performed in 21% of cases.</div></div><div><h3>Conclusion</h3><div>Performing a peripheral iridotomy during DMEK is a significant risk factor for graft detachment. DMEK significantly improves patients’ vision and restores normal pachymetry.</div></div><div><h3>But</h3><div>Analyser les résultats et la fréquence des complications après une kératoplastie endothéliale de la membrane de Descemet (DMEK) et évaluer les paramètres associés à la survenue de ces complications.</div></div><div><h3>Méthodes</h3><div>Une étude rétrospective multicentrique portant sur 143 procédures de DMEK réalisées consécutivement par cinq chirurgiens entre juin 2018 et mars 2021 a été réalisée. Les caractéristiques chirurgicales propres à chaque opérateur et les caractéristiques des greffons ont été recueillies. La meilleure acuité visuelle corrigée (MAVC), la pachymétrie centrale, la densité cellulaire endothéliale, étaient recueillies à un mois, trois mois, six mois et 12 mois. Les complications postopératoires et les procédures secondaires (<em>rebubbling</em> et regreffe) étaient recueillies.</div></div><div><h3>Résultats</h3><div>La MAVC moyenne à un an était de 0,17 (±0,19) logMAR. Il existait un shift hypermétropique moyen à un an de +0,26 dioptries. La pachymétrie moyenne à 1 an était de 526 (±53) μm. La densité cellulaire endothéliale moyenne à un an était de 1164 (±479) cellules/mm<sup>2</sup>. Le décollement du greffon concernait 51 % des procédures, et était associé significativement à la réalisation d’une iridotomie peropératoire (OR<!--> <!-->=<!--> <!-->2,8) [IC95 % : 1,2–6,6]. Le rebubbling concernait 34 % des procédures et une nouvelle greffe était réalisée dans 21 % des cas.</div></div><div><h3>Conclusion
{"title":"Outcomes and safety of Descemet's membrane endothelial keratoplasty (DMEK) as a surgical treatment for corneal endothelial dysfunction: A multicenter study","authors":"A. Aulanier, N. Todd, N. Stolowy, M. Gonzalvez, T. David","doi":"10.1016/j.jfo.2024.104406","DOIUrl":"10.1016/j.jfo.2024.104406","url":null,"abstract":"<div><h3>Purpose</h3><div>To analyze the outcomes and frequency of complications after Descemet's membrane endothelial keratoplasty (DMEK) and evaluate the parameters associated with the occurrence of these complications.</div></div><div><h3>Methods</h3><div>A multicenter retrospective study of 143 DMEK procedures performed consecutively by five surgeons between June 2018 and March 2021 was performed. Surgeon-specific surgical and graft characteristics were also assessed. Data on best-corrected visual acuity (BCVA), central pachymetry, and endothelial cell density (ECD) were collected at one, three, six, and 12<!--> <!-->months. Postoperative complications and secondary procedures (rebubbling and regrafting) were also recorded.</div></div><div><h3>Results</h3><div>The mean BCVA at one year was 0.17 logMAR (±0.19). There was a mean hyperopic shift at one year of +0.26 diopters. The mean pachymetry at one year was 526<!--> <!-->μm (±53). The mean ECD at one year was 1164<!--> <!-->cells/mm<sup>2</sup> (±479). Graft detachment occurred in 51% of the procedures and was significantly associated with the performance of an intraoperative iridotomy (OR<!--> <!-->=<!--> <!-->2.8) [95% CI: 1.2–6.6]. Rebubbling occurred in 34% of the procedures, and a new graft was performed in 21% of cases.</div></div><div><h3>Conclusion</h3><div>Performing a peripheral iridotomy during DMEK is a significant risk factor for graft detachment. DMEK significantly improves patients’ vision and restores normal pachymetry.</div></div><div><h3>But</h3><div>Analyser les résultats et la fréquence des complications après une kératoplastie endothéliale de la membrane de Descemet (DMEK) et évaluer les paramètres associés à la survenue de ces complications.</div></div><div><h3>Méthodes</h3><div>Une étude rétrospective multicentrique portant sur 143 procédures de DMEK réalisées consécutivement par cinq chirurgiens entre juin 2018 et mars 2021 a été réalisée. Les caractéristiques chirurgicales propres à chaque opérateur et les caractéristiques des greffons ont été recueillies. La meilleure acuité visuelle corrigée (MAVC), la pachymétrie centrale, la densité cellulaire endothéliale, étaient recueillies à un mois, trois mois, six mois et 12 mois. Les complications postopératoires et les procédures secondaires (<em>rebubbling</em> et regreffe) étaient recueillies.</div></div><div><h3>Résultats</h3><div>La MAVC moyenne à un an était de 0,17 (±0,19) logMAR. Il existait un shift hypermétropique moyen à un an de +0,26 dioptries. La pachymétrie moyenne à 1 an était de 526 (±53) μm. La densité cellulaire endothéliale moyenne à un an était de 1164 (±479) cellules/mm<sup>2</sup>. Le décollement du greffon concernait 51 % des procédures, et était associé significativement à la réalisation d’une iridotomie peropératoire (OR<!--> <!-->=<!--> <!-->2,8) [IC95 % : 1,2–6,6]. Le rebubbling concernait 34 % des procédures et une nouvelle greffe était réalisée dans 21 % des cas.</div></div><div><h3>Conclusion","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 3","pages":"Article 104406"},"PeriodicalIF":1.2,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.jfo.2024.104308
T. Abdellaoui , S. Sebbata , A. Zaizi , S. Bouabbadi , Y. Mouzari , A. Oubaaz
{"title":"From the thigh to the eye: Management of necrotizing scleritis using fascia lata graft","authors":"T. Abdellaoui , S. Sebbata , A. Zaizi , S. Bouabbadi , Y. Mouzari , A. Oubaaz","doi":"10.1016/j.jfo.2024.104308","DOIUrl":"10.1016/j.jfo.2024.104308","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 1","pages":"Article 104308"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.jfo.2024.104114
L. Van Den Eeckhaute, B. Docquier, L. Postelmans
{"title":"Multimodal imaging, electrophysiology and follow-up of “Dark without Pressure”: Case report","authors":"L. Van Den Eeckhaute, B. Docquier, L. Postelmans","doi":"10.1016/j.jfo.2024.104114","DOIUrl":"10.1016/j.jfo.2024.104114","url":null,"abstract":"","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 1","pages":"Article 104114"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：